EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Innovo GenMax MTB-RIF/INH: a moderate-complexity automated NAAT for rapid simultaneous detection of Mycobacterium tuberculosis complex and rifampin/isoniazid resistance

Xichao Ou, Bing Zhao, Huiwen Zheng, Ruida Xing, Qian Sun, Zhonghua Qin, Lixia Zhang, Kai Cui, Yuanyuan Song, Yang Zheng, Yang Zhou, Shengfen Wang und 2 weitere

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1600170 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Xichao Ou und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chi…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Rifampin, Isoniazid, Antitubercular Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Given the increase of treatment failure, relapse and acquired resistance observed in isoniazid (INH) resistance, there is an urgent to improve rifampin (RIF) -priority based diagnostic strategies. Therefore, we evaluated the performance of Innovo GenMax MTB-RIF/INH (GenMax), a moderate- complexity automated nucleic acid amplification test (NAAT), for detecting Mycobacterium tuberculosis complex (MTBC) and resistance to RIF and INH.

Methods

Analytical sensitivity (limit of detection, LOD) was determined using serial dilutions of Mycobacterium tuberculosis H37Rv (ATCC 27249) strains. Diagnostic accuracy was assessed in clinical sputum specimens against microbiological reference standards (MRS: positive by smear microscopy, culture or Xpert MTB/RIF for diagnosis of TB) and phenotypic drug susceptibility testing (DST). Discordant results were resolved by sequencing resistance genes ( IS6110 , rpoB , katG , inhA , ahpC ) and follow-up diagnosis results.

Results

GenMax demonstrated a calculated LOD of 8.8 CFU/mL (95% CI: 7.4-11.4) for MTBC, 674.1 CFU/mL (95% CI: 578.8-923.5) for RIF resistance, and 747.3 CFU/mL (95% CI: 613.7-1081.3) for INH resistance. In clinical evaluation, the sensitivity and specificity for MTBC detection were 97.52% (95% CI: 92.38–99.36) and 93.65% (95% CI: 88.91–96.53), respectively. For RIF and INH resistance, sensitivities were 88.46% (95% CI: 68.72–96.97) and 85.19% (95% CI: 65.39–95.14), with specificity of 92.42% (95% CI: 82.50-97.18) and 94.12% (95% CI: 84.86-98.10).

Conclusion

Innovo GenMax MTB-RIF/INH is a rapid and automated assay with high sensitivity for MTBC detection, suitable for decentralized settings. While its performance for RIF/INH resistance detection is competitive with existing assays, its sensitivity remains gaps relative to WHO targets. Further optimization, particularly through expanded probe coverage, is needed to bridge this gap and ensure reliable detection in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisRifampinIsoniazidAntitubercular AgentsTuberculosis, Multidrug-ResistantNucleic Acid Amplification TechniquesDrug Resistance, BacterialHumansSensitivity and SpecificityMicrobial Sensitivity TestsSputumTuberculosisLimit of Detection

Stichwörter der Autor:innen

drug resistanceisoniazidrapid molecular diagnosisrifampintuberculosis

Substanzen

RifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, Laboratory of Respirat…
  • Microbial Inspection Department, Changping District Center for Disease Control and Prevention, Beijing, China.
  • Center for Accurate Detection of Tuberculosis, Tianjin Haihe Hospital, Tianjin, China.

Zitieren

APA

Ou, X., Zhao, B., Zheng, H., Xing, R., Sun, Q., Qin, Z., Zhang, L., Cui, K., Song, Y., Zheng, Y., Zhou, Y., Wang, S., Xia, H., & Zhao, Y. (2025). Innovo GenMax MTB-RIF/INH: a moderate-complexity automated NAAT for rapid simultaneous detection of Mycobacterium tuberculosis complex and rifampin/isoniazid resistance. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1600170

Vancouver

Ou X, Zhao B, Zheng H, Xing R, Sun Q, Qin Z, et al. Innovo GenMax MTB-RIF/INH: a moderate-complexity automated NAAT for rapid simultaneous detection of Mycobacterium tuberculosis complex and rifampin/isoniazid resistance. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1600170

BibTeX
@article{Ou2025,
  author = {Ou, Xichao and Zhao, Bing and Zheng, Huiwen and Xing, Ruida and Sun, Qian and Qin, Zhonghua and Zhang, Lixia and Cui, Kai and Song, Yuanyuan and Zheng, Yang and Zhou, Yang and Wang, Shengfen and Xia, Hui and Zhao, Yanlin},
  title = {Innovo GenMax MTB-RIF/INH: a moderate-complexity automated NAAT for rapid simultaneous detection of Mycobacterium tuberculosis complex and rifampin/isoniazid resistance},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1600170}
}
Kostenlos starten →